New Filings & Updated Terms (ending 3.6.20am)

NEW FILINGS

Company: Pulmonx Corporation
Symbol: LUNG
Description: They are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD).
Shares: TBD
Price Range: TBD
Trade Date: TBD
Underwriter(s): BofA Securities, Morgan Stanley
Co-Manager(s): Stifel, Wells Fargo Securities, Canaccord Genuity
Filed: 2-28-20
Listed Cash Raise: $86.25m

Company: Accolade Inc.
Symbol: ACCD
Description: They provide personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits.
Shares: TBD
Price Range: TBD
Trade Date: TBD
Underwriter(s): Goldman Sachs, Morgan Stanley, BofA Securities, Piper Sandler, Credit Suisse
Co-Manager(s): William Blair, Baird, SVB Leerink
Filed: 2-28-20
Listed Cash Raise: $100m

Company: Oric Pharmaceuticals Inc.
Symbol: ORIC
Description: They are a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer.
Shares: TBD
Price Range: TBD
Trade Date: TBD
Underwriter(s): J.P. Morgan, Citigroup, Jefferies, Guggenheim Securities
Filed: 2-28-20
Listed Cash Raise: $86.25mimara

Company: Procore Technologies Inc.
Symbol: PCOR
Description: They are a leading provider of cloud-based construction management software, and are helping transform one of the oldest, largest, and least digitized industries in the world.
Shares: TBD
Price Range: TBD
Trade Date: TBD
Underwriter(s): Goldman Sachs, J.P. Morgan, Barclays, Jefferies
Co-Manager(s): Canaccord Genuity, KeyBanc Capital, Oppenheimer, Piper Sandler, Stifel, William Blair
Filed: 2-28-20
Listed Cash Raise: $100m

TERMS ADDED

Company: Imara Corp
Symbol: IMRA
Description: They are a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies.
Shares: 4.45 million
Price Range: $16.00-$18.00
Market Cap: $261m-$294m
Trade Date: Thursday, March 12
Underwriter(s): Morgan Stanley, Citigroup, SVB Leerink
Terms Added: 3-3-20